Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News HCW Biologics Inc HCWB

Healthcare Biotechnology
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat... see more

Recent & Breaking News (NDAQ:HCWB)

HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

GlobeNewswire 11 days ago

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic

GlobeNewswire March 17, 2026

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances

GlobeNewswire March 16, 2026

HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter

GlobeNewswire March 2, 2026

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

GlobeNewswire February 17, 2026

HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune

GlobeNewswire February 13, 2026

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire November 19, 2025

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

GlobeNewswire November 18, 2025

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

GlobeNewswire November 14, 2025

HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire November 10, 2025

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

GlobeNewswire November 7, 2025

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment

GlobeNewswire October 22, 2025

HCW Biologics to Participate in the 2025 Maxim Growth Summit

GlobeNewswire October 16, 2025

HCW Biologics' Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire October 16, 2025

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment About its Proprietary T-Cell Engager Program

GlobeNewswire September 30, 2025

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

GlobeNewswire September 18, 2025

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

GlobeNewswire September 16, 2025

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

GlobeNewswire September 9, 2025

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

GlobeNewswire August 25, 2025

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

GlobeNewswire August 18, 2025

Podcasts